de Seze Jérôme, Clerc Christine, Béreau Matthieu, Bourre Bertrand, Zephir Hélène, Collongues Nicolas, Kremer Laurent, Vermersch Patrick, Bigaut Kevin
Clinical Investigation Center (CIC), CHU Strasbourg, France.
Department de Neurology, CHU Strasbourg, France.
Mult Scler J Exp Transl Clin. 2024 Feb 29;10(1):20552173241233952. doi: 10.1177/20552173241233952. eCollection 2024 Jan-Mar.
To assess the efficacy of dalfampridine in patients with neuromyelitis optica spectrum disorder.
We included 15 consecutive patients, who were started on a treatment of dalfampridine 10 mg twice daily for 2 weeks. Efficacy assessment was based on walking ability improvement using Timed-25-Foot Walk and 12-item Multiple Sclerosis Walking Scale tests.
The mean Timed-25-Foot Walk score was reduced from 14.8 (±2.4) to 11.3 (±1.9) seconds ( = 0.01). The mean score on the 12-item Multiple Sclerosis Walking Scale was reduced from 41.2 (±3.5) to 31.4 (±3.2) ( = 0.004).
Dalfampridine seems to be useful for symptomatic treatment of walking impairment in neuromyelitis optica spectrum disorder.
评估氨吡啶对视神经脊髓炎谱系障碍患者的疗效。
我们纳入了15例连续的患者，开始给予氨吡啶10毫克每日两次治疗，持续2周。疗效评估基于使用25英尺计时步行测试和12项多发性硬化症步行量表测试来评估步行能力的改善情况。
25英尺计时步行测试的平均得分从14.8（±2.4）秒降至11.3（±1.9）秒（P = 0.01）。12项多发性硬化症步行量表的平均得分从41.2（±3.5）降至31.4（±3.2）（P = 0.004）。
氨吡啶似乎对视神经脊髓炎谱系障碍患者步行障碍的症状性治疗有用。
